Market closed
Larimar Therapeutics/$LRMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Ticker
$LRMR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
65
Website
LRMR Metrics
BasicAdvanced
$122M
-
-$1.32
0.77
-
Price and volume
Market cap
$122M
Beta
0.77
52-week high
$11.20
52-week low
$1.61
Average daily volume
947K
Financial strength
Current ratio
8.019
Quick ratio
7.532
Long term debt to equity
2.361
Total debt to equity
2.978
Management effectiveness
Return on assets (TTM)
-38.36%
Return on equity (TTM)
-63.58%
Valuation
Price to book
0.71
Price to tangible book (TTM)
0.71
Price to free cash flow (TTM)
-1.642
Growth
Earnings per share change (TTM)
56.34%
3-year earnings per share growth (CAGR)
-23.59%
What the Analysts think about LRMR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.
LRMR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LRMR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LRMR News
AllArticlesVideos
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·4 weeks ago
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
GlobeNewsWire·2 months ago
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Larimar Therapeutics stock?
Larimar Therapeutics (LRMR) has a market cap of $122M as of April 20, 2025.
What is the P/E ratio for Larimar Therapeutics stock?
The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of April 20, 2025.
Does Larimar Therapeutics stock pay dividends?
No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next Larimar Therapeutics dividend payment date?
Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Larimar Therapeutics?
Larimar Therapeutics (LRMR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.